Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Martin Dominkus is active.

Publication


Featured researches published by Martin Dominkus.


Clinical Orthopaedics and Related Research | 2001

Long-term followup of uncemented tumor endoprostheses for the lower extremity.

Florian Mittermayer; Petra Krepler; Martin Dominkus; Eva Schwameis; Maria Sluga; Harald Heinzl; Rainer Kotz

Between 1982 and 1989, 100 primary lower limb reconstructions were done using the Kotz Modular Femur Tibia Reconstruction System after resection of a malignant tumor. In 32 patients a proximal femur prosthesis was implanted, in 40 patients a distal femur prosthesis was implanted, in 19 patients a proximal tibia component was implanted, in four patients a total femur prosthesis was implanted, and in five patients a total knee prosthesis was implanted. The Kaplan-Meier estimate of the overall survival rate of the prostheses was 85% after 3 years, 79% after 5 years, and 71% after 10 years. The most common reason for implant failure was aseptic loosening in 27% of patients (11 patients; range, 10–121 months) after the initial operation. The other reasons for revision surgery were implant fracture (n 5 4) and infection (n 5 4). Early repair of prostheses-related minor complications, such as worn polyethylene bushings, resulted in a statistically significant reduction of implant failure. After a median followup of 127.5 months after the initial surgery, 51 patients had died and eight patients were lost to followup. Forty-one patients were evaluated clinically and radiologically using the Musculoskeletal Tumor Society score and the radiologic implant evaluation system of the International Symposium on Limb Salvage; these 41 patients had a mean of 80% (range, 40%–100%) of the normal functional capability.


European Journal of Cancer | 2009

Prognostic factors and outcomes for osteosarcoma: an international collaboration

Emilios E. Pakos; Andreas D. Nearchou; Robert J. Grimer; Haris D. Koumoullis; Adesegun Abudu; Jos A.M. Bramer; L. Jeys; Alessandro Franchi; Guido Scoccianti; Domenico Andrea Campanacci; Rodolfo Capanna; Jorge Aparicio; Marie-Dominique Tabone; Gerold Holzer; Fashid Abdolvahab; Philipp T. Funovics; Martin Dominkus; Inci Ilhan; Su Gülsün Berrak; Ana Patiño-García; Luis Sierrasesúmaga; Mikel San-Julian; Moira Garraus; Antonio Sergio Petrilli; Reynaldo Jesus Garcia Filho; Carla Renata Pacheco Donato Macedo; Maria Teresa de Seixas Alves; Sven Seiwerth; Rajaram Nagarajan; Timothy P. Cripe

We aimed to evaluate the prognostic significance of traditional clinical predictors in osteosarcoma through an international collaboration of 10 teams of investigators (2680 patients) who participated. In multivariate models the mortality risk increased with older age, presence of metastatic disease at diagnosis, development of local recurrence when the patient was first seen, use of amputation instead of limb salvage/wide resection, employment of unusual treatments, use of chemotherapeutic regimens other than anthracycline and platinum and use of methotrexate. It was also influenced by the site of the tumour. The risk of metastasis increased when metastatic disease was present at the time the patient was first seen and also increased with use of amputation or unusual treatment combinations or chemotherapy regimens not including anthracycline and platinum. Local recurrence risk was higher in older patients, in those who had local recurrence when first seen and when no anthracycline and platinum were used in chemotherapy. Results were similar when limited to patients seen after 1990 and treated with surgery plus combination chemotherapy. This large-scale international collaboration identifies strong predictors of major clinical outcomes in osteosarcoma.


Sarcoma | 2000

Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial

Thomas Brodowicz; Eva Schwameis; Joachim Widder; Gabriele Amann; Christoph Wiltschke; Martin Dominkus; Reinhard Windhager; Peter Ritschl; Richard Pötter; Rainer Kotz; Christoph C. Zielinski

Purpose. The present prospective randomized adjuvant trial was carried out to compare the toxicity, feasibility and efficacy of augmented chemotherapy added to hyperfractionated accelerated radiotherapy after wide or marginal resection of grade 2 and grade 3 soft tissue sarcoma (STS).Patients and methods. Fifty-nine patients underwent primary surgery by wide or marginal excision and were subsequently randomized to receive radiotherapy alone or under the addition of six courses of ifosfamide (1500 mg/m(2) , days 1-4), dacarbazine (DTIC) (200 mg/m(2) , days 1-4) and doxorubicin (25 mg/m(2) , days 1-2) administered in 14-day-intervals supported by granulocyte-colony stimulating factor (30 x 10(6) IU/day, s.c.) on days 5-13. According to the randomization protocol, 28 patients received radiotherapy only, whereas 31 patients were treated with additional chemotherapy.Results. The relative ifosfamide-doxorubicin-DTIC (IFADIC) dose intensity achieved was 93%. After a mean observation period of 41+/-19.7 months (range, 8.1-84 months), 16 patients (57%) in the control group versus 24 patients (77%) in the chemotherapy group were free of disease (p>0.05).Within the control group, tumor relapses occurred in 12 patients (43%;six patients with distant metastases, two with local relapse, four with both) versus seven patients (23%; five patients with distant metastases, one with local recurrence, one with both) from the chemotherapy group. Relapse-free survival (RFS) (p=0.1), time to local failure (TLF) (p=0.09), time to distant failure (TDF) (p=0.17) as well as overall survival (OS) (p=0.4) did not differ significantly between the two treatment groups. Treatment-related toxicity was generally mild in both treatment arms.Conclusion. We conclude that the safety profile of intensified IFADIC added to radiotherapy was manageable and tolerable in the current setting. Inclusion of intensified IFADIC was not translated into a significant benefit concerning OS, RFS, TLF andTDF as compared with radiotherapy only, although a potential benefit of chemotherapy for grade 3 STS patients needs to be validated in prospective randomized trials including larger patient numbers.


European Surgical Research | 2004

In vivo and in vitro Cellular Ingrowthinto a New Generation of Artificial Ligaments

K. Trieb; H. Blahovec; G. Brand; M. Sabeti; Martin Dominkus; R. Kotz

Artificial ligaments are a useful tool in ligament reconstruction. Although the new generation of artificial ligaments shows encouraging clinical results, in contrast to earlier generations studies on the biological properties are lacking. Biopsies were taken from a ligament advancement reinforcement system (LARS) 6 months after implantation and investigated by histochemistry. An in vitro study seeding human fibroblasts or osteoblast-like cells (up to 106 cells for 21 days) on ligament pieces (5 × 5 mm) was conducted and analyzed by histochemistry. The biopsies showed complete cellular and connective tissue ingrowth in the LARS ligament. In vitro fibroblasts and osteoblast-like cells encapsulated the fibers by building a cellular net around them. To our knowledge, these findings demonstrate for the first time the cellular ingrowth into the LARS ligament. This mechanism might explain the strength and the inert behavior of the ligament without the synovialitis shown in clinical studies.


Clinical Orthopaedics and Related Research | 2002

Reconstruction of the pelvis after tumor resection in children and adolescents

Eva Schwameis; Martin Dominkus; Petra Krepler; Ronald Dorotka; Susanna Lang; Reinhard Windhager; Rainer Kotz

Thirty patients younger than 19 years with malignant bone tumors of the pelvis were treated by limb salvage surgery between 1970 and 1998. Functional and oncologic results were reviewed retrospectively. In 10 patients the defect was reconstructed by an endoprosthesis and in 20 patients reconstruction by autologous grafts (n = 7), allograft and prosthesis combinations (n = 2), bone cement reconstruction (n = 1), iliosacral arthrodesis (n = 1), modified Girdlestone procedure (n = 3), or resection without reconstruction (n = 6) was done. Three and one-half reoperations per patient were necessary postoperatively after allograft reconstruction, 2.5 reoperations per patient were necessary after endoprosthetic reconstruction, and 0.8 reoperations per patient were necessary after other or no reconstruction. After a mean followup of 52 months (range, 2–241 months), 17 patients were alive, 15 of whom were continuously disease-free, and 13 patients had died of their disease. Functional ratings were 81% after autograft, 73% after allograft, and 60% after endoprosthetic reconstruction. Defect reconstruction varied according to the type of resection. Type I resections were best reconstructed by biologic methods. Endoprosthetic reconstruction after periacetabular resection with the advantage of preservation of a functional hip and body integrity was associated with a high rate of complications and reoperations. Its role compared with allograft reconstruction, modified Girdlestone procedure, or no reconstruction requires additional investigation.


Clinical Orthopaedics and Related Research | 2005

Prevalence of aneurysmal and solitary bone cysts in young patients.

Harald Zehetgruber; Barbara Bittner; Diego Gruber; Petra Krepler; Klemens Trieb; Rainer Kotz; Martin Dominkus

Aneurysmal and solitary bone cysts develop most commonly during skeletal growth. The objective of our epidemiologic study was to evaluate the prevalence, recurrence rate, and probability of recurrence-free survival for aneurysmal and solitary bone cysts in young patients. We did a population-based analysis of 141 histologically confirmed cases. Seventy-three patients with aneurysmal bone cysts and 68 patients with solitary bone cysts were registered. The annual prevalence was 0.32 per 100,000 individuals (range, 0-1.238) for aneurysmal cysts, with a 1.8:1 male to female ratio and a median age of the patients of 11.1 years (range, 1-19.7 years). For solitary bone cysts, the calculated annual prevalence was 0.30 (range, 0-0.963) with a median age of the patients of 1.1 years (range, 0.5-19.9) and a 1.96:1 male to female ratio. Recurrent lesions occurred frequently in young males. Secondary aneurysmal bone cysts were observed only in females. During skeletal growth, aneurysmal and juvenile bone cysts more often occur in males with a peak prevalence at approximately 11 years of age. A greater prevalence of aneurysmal bone cysts in young individuals is associated with skeletal growth and immaturity. Young age and male gender are associated with an increased risk of local recurrence.


Journal of Bone and Joint Surgery, American Volume | 2007

Metatarsal reconstruction with use of free vascularized osteomyocutaneous fibular grafts following resection of malignant tumors of the midfoot. A series of six cases.

Cyril D. Toma; Martin Dominkus; Martin Pfeiffer; Pietro Giovanoli; Ojan Assadian; R. Kotz

BACKGROUND Bone and soft-tissue sarcomas are uncommon, and their location in the foot is extremely rare. While limb salvage has become the standard of care in the treatment of sarcoma in an extremity, the unique anatomy of the foot presents challenges in reconstructing a viable and functional limb. METHODS Between 1998 and 2005, we used free microvascularized osteomyocutaneous fibular grafts to reconstruct the defects created after extensive midfoot resection in six consecutive patients with a primary malignant tumor. In all but one patient, the extent of the resection involved at least two metatarsals. The mean age (and standard deviation) at the time of the operation was 30+/-13 years. At the final follow-up examination, clinical and radiographic evaluations were performed on all patients, and functional outcome and quality of life were assessed with use of the Musculoskeletal Tumor Society score, the American Orthopaedic Foot and Ankle Society Score, and the Toronto Extremity Salvage Score. RESULTS The median duration of follow-up was 52.2 months. Limb salvage was achieved in five patients. In the remaining patient, amputation was necessary because of flap failure. Revision surgery was necessary in all patients because of complications (skin ulcerations in three patients; hematoma in two patients; and infection, necrosis of the second toe, and flap necrosis in one patient each). At the time of final follow-up, five patients had satisfactory function and reported good quality of life. The average Musculoskeletal Tumor Society, American Orthopaedic Foot and Ankle Society, and Toronto Extremity Salvage scores were 82%, 75 points, and 92%, respectively. At the time of the final follow-up, five patients had no evidence of disease and one patient had disease. CONCLUSIONS Following the resection of a malignant tumor in the midfoot, the use of microvascularized osteomyocutaneous fibular grafts has proven to be a successful surgical technique, offering an alternative to ablative surgery with functional restoration of the salvaged limb.


Clinical Orthopaedics and Related Research | 2001

Growth prediction in extendable tumor prostheses in children.

Martin Dominkus; Petra Krepler; Eva Schwameis; Reinhard Windhager; Rainer Kotz

Limb salvage procedures for malignant bone tumors of the lower limb in children usually involve resection of at least one growing physis. To achieve equal leg length, reconstruction relies on accurate prediction of the remaining growth potential of the child. The current authors present the results of predicted growth versus actual prosthetic elongation observed in a group of 15 children fitted with extendable tumor endoprostheses of the lower limb who subsequently have reached skeletal maturity. All patients had at least one of the distal femoral or proximal tibial physes resected for a primary malignant bone tumor. Eight patients underwent distal femoral resection, four patients underwent proximal tibial resection, and three patients had total resection of the femur. All patients received custom-made Howmedica extendable prostheses. In two patients, a newly developed automatic elongation module was used. At followup, between 70 and 158 months, the patients achieved a mean elongation of the surgically treated limb of 10.4 cm (range, 1.1–19.5 cm), which exceeded the predicted growth by 24.3%. Final leg length discrepancies did not exceed 1 cm. Using incremental extendable tumor endoprostheses, individual adaptation of the elongation procedures could be achieved for equalization of leg length discrepancies in children after resection of primary malignant bone tumors of the lower limb.


Clinical Orthopaedics and Related Research | 2001

The role of surgery and resection margins in the treatment of Ewing's sarcoma.

Maria Sluga; Reinhard Windhager; Susanna Lang; Harald Heinzl; Petra Krepler; Florian Mittermayer; Martin Dominkus; Andreas Zoubek; Rainer Kotz

Because of the enormous progress in surgery in the treatment of patients with tumors, the current study analyzed the influence of wide surgical resection margins on the outcome of patients with Ewing’s sarcoma. Between 1980 and 1994, 86 patients were treated with systemic therapy and surgery (biopsy in six patients, tumor resection in 80 patients). Forty-four patients also had radiation therapy. The 5-year overall survival was 56.8% (5-year disease-free survival, 59.4%). The 5-year overall survival after radical or wide resection was 60.2% (5-year disease-free survival, 58.2%), in comparison with 40.1% (46.7%) after marginal or intralesional resection. Two patients with inadequate resection margins had local recurrences. In addition to the influence of neoadjuvant chemotherapy for higher survival rates (5-year overall survival with a good response was 80.2% versus 41.7% with a poor response), adequate surgical margins significantly affect the outcome for patients with Ewing’s sarcoma.


Clinical Orthopaedics and Related Research | 2006

Reconstructing the extensor apparatus with a new polyester ligament

Martin Dominkus; Manuel Sabeti; Cyril D. Toma; Farshid Abdolvahab; Klemens Trieb; Rainer Kotz

We analyzed the clinical outcome of patients who had reconstruction of the extensor apparatus with a new polyester ligament after extensive resection of malignant tumors around the knee. Twenty-two patients were included; 19 were evaluated after a mean followup of 44 months (range, 8-67 months) to assess active and passive knee range of motion, walking ability, need for revision, and TESS and Enneking scores. The patients were divided into two groups; patients in Group A had a weakened extensor mechanism and patients in Group B had a completely dissected extensor mechanism. Seven patients had excellent knee function with an extension lag less than 5°. Five patients had an extension deficit less than 20°, three patients had a deficit less than 40°, and four patients could not extend their limb against gravity. However, all patients were able to walk without walking aids. They had a mean Enneking score of 83 points and a mean TESS score of 82 points. Patients who had distal femur resections had worse results than patients who had proximal tibia resections. The LARS® ligament proved promising for augmentation and complete reconstruction of the extensor apparatus of the knee after extensive tumor resection, with excellent and good results in 59% of patients.Level of Evidence: Level II, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

Collaboration


Dive into the Martin Dominkus's collaboration.

Top Co-Authors

Avatar

Gabriele Amann

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Philipp T. Funovics

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Petra Krepler

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Reinhard Windhager

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

R. Kotz

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cyril D. Toma

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Stephan E. Puchner

Medical University of Vienna

View shared research outputs
Researchain Logo
Decentralizing Knowledge